

14<sup>th</sup> Netherlands Conference on HIV Pathogenesis,  
Epidemiology, Prevention and Treatment  
Tuesday 23 November 2021

# Book of Speakers



We would like to thank all presenters, abstract submitters and chairs for sharing and discussing their research results.

**Correspondence to:**

organisation@nchiv.org

**© 2021 Stichting NCHIV**

All rights reserved. No permission is given for the reproduction or publication of the content of this publication in any form or by any means, or storage in any retrieval system without prior written approval by the authors.

Production: Sabina Beeke, Yunka de Waart  
Art Direction and DTP: GRAFICARE, Amsterdam

## Organisation

The 14<sup>th</sup> Netherlands Conference on HIV Pathogenesis, Epidemiology, Prevention and Treatment (NCHIV) is organised by:



Rijksinstituut voor Volksgezondheid  
en Milieu  
Ministerie van Volksgezondheid,  
Welzijn en Sport



aighd | AMSTERDAM INSTITUTE FOR  
GLOBAL HEALTH & DEVELOPMENT



## Acknowledgements

This conference is made possible through contributions from:

### Platinum sponsors

ViiV Healthcare BV

Gilead Sciences Netherlands BV

### Gold sponsor

MSD Netherlands

### Silver sponsor

Janssen-Cilag BV

Sponsors have had no input into the development of the NCHIV programme



# Table of Contents

Alexandra Blenkinsop	6	Maike Noorman	15
Angela Colbers	6	Marc Blaauw	15
Angela Schriek	6	Marc van der Valk	15
Anna Maria Żakowicz	6	Maria Prins	16
Anusca Rader	7	Marieke Nühn	16
Amsterdam UMC	7	Marit van Gils	16
Ard van Sighem	7	Mark Vermeulen	17
Bertus Tempert	7	Mouraya Hussein	17
Casper Rokx	7	Myrthe Verburgh	17
Charissa Verkade	8	Natasja van Holten	18
Colette Smit	8	Neeltje Kootstra	18
Daphne van Wees	8	Nicolas Chomont	18
David Burger	9	Ninée Buchholtz	19
Edwin Oraki	9	Patrick Oomen	19
Eline Op de Coul	9	Peter Reiss	19
Feline de la Court	9	Philippe Adam	20
Ferdinand Wit	10	Piter Oosterhof	20
Glenda Gray	10	Renée Schreurs	20
Gloria Summerville	10	Reon van Dyk	20
Godelieve de Bree	11	Rogier Sanders	21
Hanne Zimmermann	11	Sarah Stutterheim	21
Haoyi Wang	11	Shirley Man	21
Janneke Heijne	11	Silke David	22
Jason van Genderen	12	Soerajja Bhoelan	22
Jeffrey Koole	12	Stephanie Gumbs	22
Jeffrey Umotoy	12	Steven de Taeye	22
Jelle van Schooten	13	Sven Danner	23
Jori Symons	13	Tamika Marcos	23
Judith Branger	13	Tania Mudrikova	23
Kennedy d'Abreu de Paulo	14	Thomas Nieuwenstein	23
Kim Sigaloff	14	Tom Jacobs	24
Lavina Gharu	14	Vita Jongen	24
Leanne Helgers	14	Wilma Brokking	24
Louise van Eekeren	15	Wouter Bierman	24



**Alexandra Blenkinsop**  
*AIGHD, Imperial College London*

Alexandra Blenkinsop is a postdoctoral researcher based at Imperial College London, working alongside the HIV Transmission Elimination Amsterdam (H-TEAM) initiative, using quantitative methods to inform targeted HIV prevention strategies. She holds a PhD in medical statistics, and has expertise in phylogenetics and mathematical modelling to characterise HIV transmissions and understand sources of new infections.

O5



**Angela Colbers**  
*Radboudumc*

Angela Colbers is a researcher at the Pharmacy of the Radboud university medical center in Nijmegen, The Netherlands with a focus on pharmacology studies in pregnant women and children living with HIV. She built up a broad experience in clinical trials at pharmaceutical industry and contract research organisation before working in academia.

Her doctorate thesis entitled: “Exposure to antiretroviral agents in HIV-infected pregnant women: not too much - not too little”, was rewarded with the “PhD award 2015 for the best thesis” by the Radboud Institute for Health Sciences. She coordinates the PANNA-network, a European network studying pharmacokinetics of antiretroviral agents in HIV-infected pregnant women.

Angela is co-chair of the Pediatric Antiretroviral Working Group (WHO advisory group). She co-organized WHO and IMPAACT workshops to enhance (pharmacology) studies in pregnant and lactating women.

S11



**Angela Schriek**  
*Amsterdam UMC*

After completing her bachelor’s in pharmaceutical sciences at the University of Leiden (2017), Angela proceeded to pursue a master’s degree in pharmaceutical sciences at the University of Leiden (2019) and wrote her thesis about the interplay between antibody subclasses in relation to effector functions. In 2020, she started working as a PhD student in the group of Dr. van Gils, at the department of Experimental Immunology, at the University of Amsterdam where she focusses on the development of nanobodies with antibody effector functions for HIV cure.

S17



**Anna Maria Żakowicz**  
*AHF Europe*

Anna Maria Żakowicz is Deputy Bureau Chief and Director of Programs at AHF (AIDS Healthcare Foundation) Europe in Amsterdam, the Netherlands. She focuses on implementation of people-centered care approaches in HIV testing, treatment and care and prevention. She is committed to putting into practice concepts of integration, task-shifting, user-driven care and patients’ involvement in co-production of care. She works across Europe; Eastern Europe has a special place in her heart. She serves on the Board of Trustees of Aidsfonds. Currently she is engaged in the work of WHO Linkage to Care TWG and Quality of Live TWG. She served as a co-chair of Global Network of People Who Live with HIV (GNP+), Civil Society Forum on HIV (CSF), a chair of European AIDS Treatment Group (EATG) and a board member of Medicines Patent Pool (MPP). Anna Maria has a background in humanities and public health. She received her MA from Silesian University and MIH from University of Copenhagen.

S2



**Anusca Rader**  
*Amsterdam UMC*

Anusca joined the Autophagy-Directed Immunity group at the Amsterdam UMC, led by Dr. Carla Ribeiro, as a PhD candidate after graduating from Leiden University in 2020. She has a profound interest in unravelling virus-host interactions to identify novel therapeutic possibilities. Her current research focuses on elucidating and potentially blocking the transmission of HIV-1 across the intact intestinal barrier. To study intestinal HIV-1 transmission and infection she uses human intestinal organoid models and applies various techniques, including confocal microscopy, flow cytometry, and enzyme-linked immunosorbent assays.

06



**Ard van Sighem**  
*SHM*

Ard's research at Stichting HIV Monitoring involves investigating the course and the changes in the HIV epidemic in the Netherlands. To achieve this, Ard uses mathematical modelling as a tool to analyse the relevant data in the ATHENA cohort (the database maintained by Stichting HIV Monitoring) and other national data sources. Ard is also studying the HIV epidemic at a local level, for example in Rotterdam and Amsterdam in collaboration with the H-TEAM.

Ard is also interested in the more patient-specific side of the HIV epidemic. In particular, Ard works with the Antiretroviral Therapy Cohort Collaboration (ART-CC) to investigate changes in causes of death in people living with HIV. In addition, he is involved in the HIV-CAUSAL collaboration, that analyses longitudinal data using methods to target causal interference.

Lastly, Ard works together with the European Centre for Disease Control and Prevention to estimate the size of the population of people living with HIV, including those as yet undiagnosed, in Europe, and on nationwide and regional levels.


Session 1: presenter 2021 NL Monitoring Report



**Bertus Tempert**  
*Hiv vereniging*

Bertus Tempert has been working in the HIV/AIDS field for 35 years, both professionally and voluntary. He has extensive experience in working with key populations: MSM, people who use drugs, people with a migrant background and young people. He is the office manager at Aidsfonds - Soa Aids Nederland. Bertus was diagnosed with HIV in 2002. In 2017 he was elected Chair of Hiv Vereniging, the Dutch association of people with HIV.

Session 3: panel Long-acting ART: a paradigm shift?



**Casper Rokx**  
*Erasmus MC*

Casper Rokx (1983) works at the Erasmus University Medical Center (Rotterdam, Netherlands) as infectious diseases specialist where he leads the clinical HIV research unit. He finished his medical training in Zambia and combined his medical specialisation with a PhD on HIV treatment. He did postdoctorals on HIV/AIDS (prof. Anton Pozniak, London) and molecular virology (prof. Charles Boucher and dr. Tokameh Mahmoudi). He was selected in the 2016 resident's talent-class and as 2021 Erasmus MC research fellow. His research focuses on HIV 90-90-90 care cascades and cure for which he setup collaborations within Europe and Ukraine, the #aware.hiv project, and coordinates antiretroviral therapy, HIV cure and COVID-19 trials. He is a principle investigator in the Erasmus MC HIV Eradication Group, NL4Cure and EU2Cure consortia, and a NVHB scientific committee and EACS YING faculty member.

Spotlight sessions A and B: moderator



**Charissa Verkade**  
*Emma's Children Hospital*

Charissa Verkade is currently working as a resident at the children and adolescents psychiatry. During this job it is her responsibility to admit and interview new children, perform psychiatric and physical examination and evaluate the therapy and medication. Working with children is what she likes to do most as this challenges her every day and gives her a lot of energy. Besides her job Charissa works on an education project called CoMaster where they create digital content for medical students and a platform named Dokters op Hakken where they interview successful women in the medical world. Besides working Charissa likes to do kickboxing, travelling and reading. As she likes to learn about other cultures she started taking Spanish lessons. Her scientific internship gave Charissa a new challenge to explore the research world where she now does research about children living with HIV.

S32



**Colette Smit**  
*SHM*

Colette studied human nutrition and is trained as an epidemiologist at Wageningen University. After a short period working at the department of infectious disease epidemiology at the National Institute for Public Health and Environment, she subsequently started her PhD research in 2002 with the Amsterdam Cohort Studies at the Amsterdam public health service (GGD Amsterdam). This resulted in her PhD thesis entitled: '25 years of HIV: Trends in mortality, HIV-coinfections, and HIV-related risk behaviour'. Since 2006, Colette has been working as a senior researcher for Stichting HIV Monitoring, where her main areas of research are: HIV co-infections, viral hepatitis, quality of HIV care, epidemiology of HIV infection in children, and pregnancies in women living with HIV.

Session 1: presenter 2021 NL Monitoring Report



**Daphne van Wees**  
*RIVM*

Daphne van Wees (1991) graduated from the VU University in Amsterdam (MSc Health sciences: specialization Infectious Diseases and Public Health) in July 2015. In December 2019, she finished her PhD project at the National Institute for Public Health and the Environment (RIVM). This project was a combination of epidemiology, behavioural sciences and mathematical modelling to study the link between behavioural and psychological characteristics, and chlamydia transmission. She successfully defended her dissertation at Utrecht University in December 2020. From February 2020 to February 2021, she worked as a postdoctoral researcher at the Julius Center for Health Sciences and Primary Care on projects about the impact of PrEP on sexual behaviour and STI/HIV distribution in the MSM population. Since September 2020 she started working at the RIVM again as an epidemiologist/behavioural scientist. Here, she is currently working on epidemiology and behavioural science-based research projects into infectious disease transmission, such as STI, HIV, and COVID-19 and contributes to national STI/HIV surveillance.

S25





## David Burger

**Radboudumc**

David Burger (October 20, 1964) received his Pharmacy Degree at the Utrecht University, the Netherlands, in 1990 and completed his PhD thesis in 1994. After this, he moved to the Radboud University Medical Centre, Nijmegen, for his hospital pharmacist training.

Since 1997 he has been leading a research group focussing on clinical pharmacology of antimicrobial agents with emphasis on HIV, TB, fungal infections, and Hepatitis. He is a member of the Editorial Board of Liverpool drug interaction websites.

He is an Executive Editor of BJCP and serves on the editorial boards of TDM, JAIDS, JAC, Antiviral Therapy. Since April 2011 he has been appointed as a Professor of Clinical Pharmacy at the Radboud University Nijmegen. He is (co-) author of more than 500 publications in this field and has supervised more than 30 completed PhD theses. The topics of his interest are drug-drug interactions, pediatric pharmacology, therapeutic drug monitoring, and operational research in resource-limited countries.

S10



## Edwin Oraki

Edwin Oraki has been living with HIV since 2003. Edwin: “Back then, the view on social possibilities and acceptance were vastly different than now. Thanks to all of you I am proud to say despite this condition I have reached life goals such as buying a house, getting married. Later on my wife gave birth to our beautiful daughter who is now 11 years old. Because of my character I have mixed feelings about taking a daily pill. Since 8 months I am following a study at the hospital for Injectables that work for 2 months. I am happy to share my thoughts :)”

Session 3: panel Long-acting ART: a paradigm shift?



## Eline Op de Coul

**RIVM**

Eline Op de Coul is a Senior Epidemiologist and currently acting head of the STI department of the Centre for Infectious Disease Control at the National Institute for Public Health and the Environment in the Netherlands. She is the operational focal point for HIV in the Netherlands for the ECDC (European Center for Disease Control and Prevention) in Stockholm. Her expertise: epidemiology and surveillance of HIV, STIs and Hepatitis, community-based test approaches, and antenatal screening for STI. Her view: “In the Netherlands, the three '95 WHO goals' for HIV are almost reached, but some key populations are staying behind. We need more targeted community-based approaches and an open mind towards lay testing, self-testing, and peer-to-peer dissemination of tests“

S1



## Feline de la Court

**GGD Amsterdam**

Feline de la Court (1997) is a researcher and PhD student at the Public Health Service (GGD) of Amsterdam, for the Department of Infectious Diseases, Research and Prevention since 2020. She has a background in health science, holding two masters' degrees in Vitality & Ageing from Leiden University (2020) and Health Science with a specialization in prevention and public health from the Vrije Universiteit Amsterdam (2021). Her PhD project pertains to optimising HIV pre-exposure prophylaxis (PrEP) roll-out among men who have sex with men. Her research focuses on the evaluation of PrEP eligibility, uptake, and retention in relation to HIV and STI; using data from the National PrEP Program, Amsterdam Cohort studies and Amsterdam PrEP project.

S26



**Ferdinand Wit**  
***SHM, Amsterdam UMC***

Ferdinand studied medicine at the Academic Medical Center in Amsterdam and has worked as an HIV-treating physician in the Academic Medical Center since 1995. After obtaining his PhD from the University of Amsterdam in 2002, Ferdinand became the Director Science & Medical Affairs of the Amsterdam-based clinical research organisation IATEC. In 2007, Ferdinand became a senior researcher at the AMC-CPCD, which later became the AIGHD and the Department of Global Health of the Academic Medical Center. In 2015, he joined Stichting HIV Monitoring as senior researcher.

Ferdinand has collaborated closely with the research groups of prof. Joep Lange and Peter Reiss and has supervised many junior researchers and doctoral students in Amsterdam and abroad. His main scientific interests are the epidemiology and treatment of HIV, specialising in observational cohort studies in the field of HIV. Recent work includes the epidemiology and pathogenesis of HIV-related non-communicable diseases in the population of people living with HIV.

Session 1: presenter 2021 NL Monitoring Report | 03



**Glenda Gray**  
***President & CEO: SAMRC***

An NRF A1 rated scientist, CEO and President of the South African Medical Research Council (SAMRC), Professor Glenda Gray is a qualified pediatrician and co-founder of the internationally recognised Perinatal HIV Research Unit in Soweto, South Africa. Prior to her appointment at the SAMRC, she was the Executive Director of the Perinatal HIV Research Unit, an affiliate of Wits University. Glenda's global profile includes a role as Co-PI of the HIV Vaccine Trials Network (HVTN), a transnational collaboration for the development of HIV/AIDS prevention vaccines. She is also Director of International Programmes for HVTN and Chairperson of the Board of the Global Alliance for Chronic Diseases, and a member of the Institute of Medicine of the National Academies, USA. She received South Africa's highest honour - the Order of Mapungubwe - for her pioneering research in PMTCT. Other prestigious accolades include the Nelson Mandela Health and Human Rights Award for significant contributions in the field of mother-to-child transmission of HIV. Selected as one of Time's 100 Most Influential People in the World, Glenda is a recognised leader in her field. Her qualifications include an MBBCh, FCPaed (SA), DSc (honoris causa SFU), DSc (honoris causa SUN), LL.D (Rhodes).

Nummer



**Gloria Summerville**  
***Stichting Het Rode Lint***

Gloria Summerville is a cheerful Surinamese woman from Rotterdam who has had serious setbacks in her life and health, but she has managed to turn these setbacks into strength. When Gloria heard that she was HIV positive her world collapsed, but she managed to pick herself up and use her setbacks for others. Gloria wants to break down taboos surrounding HIV and support people living with and without HIV, so that they can have a more positive outlook on life. To do this, she founded Stichting Het Rode Lint. People deeply appreciate the strength she draws from her illness and her commitment to helping others.

Session 4: 40 Years of AIDS



## Godelieve de Bree

*Amsterdam UMC*

Godelieve de Bree is consultant internal medicine with subspecialty infectious disease and clinical immunology. Since 2013 she is affiliated at the Amsterdam Institute for Global Health and Development and the Academic Medical Center (AMC) in Amsterdam. Her current clinical work involves general infectious diseases and clinical immunology, specifically primary immune deficiencies. Godelieve is currently leading the translational clinical studies on acute HIV infection and phase 1 vaccination trials in the AMC. Furthermore, since 2013 she is scientific coordinator of the HIV Transmission Elimination Amsterdam (H-TEAM) initiative aiming at improving prognosis of HIV infected individuals and reducing HIV transmission in Amsterdam.

Session 2: Chair



## Hanne Zimmermann

*GGD Amsterdam, Maastricht University*

Drs. Hanne ML Zimmermann (MSc) obtained her Research Master degree in Health Sciences in 2016 from Maastricht University, in which she specialized in Epidemiology and Global Health. She is working as a PhD student at the Public Health Service of Amsterdam, Department of Infectious Diseases, Research and Prevention. Her PhD project focuses on the psychosocial impact of biomedical HIV prevention and treatment on the lives of men who have sex with men (MSM). The main topics her research focuses on are HIV pre-exposure prophylaxis (PrEP), viral load sorting, and traditional behavioral HIV prevention strategies, as well as an investigation of the burden of living with HIV among MSM now that all these new developments are available.

S15

## Haoyi Wang

*Maastricht University*

Haoyi Wang is an Epidemiologist and a PhD candidate with expertise in the related field of epidemiology, infectious diseases (HIV), public health and mathematical modelling. As such, his research is usually focusing on the epidemiological aspects on HIV interventions including HIV monitoring and HIV prevention as treatment. He is also passionate about applying Bayesian statistics into his modelling analysis as the methodological exploration and development with the combination of machine learning and Big Data Science in the fields. Currently, Haoyi Wang's research is focus on mathematical modelling on HIV interventions at Maastricht University.

S13



## Janneke Heijne

*RIVM*

Janneke Heijne is acting head of the sexually transmitted infections (STI) department at the RIVM. She specializes in combining mathematical modelling, epidemiology and social sciences to investigate the impact of interventions to control transmission of STI and HIV. She obtained her PhD at the University of Bern, Switzerland in the department of social and preventive medicine (ISPM) in 2012. She is a board member of the International Society of STD Research (ISSTD).


Spotlight session C: moderator



**Jason van Genderen**  
*Emma's Children Hospital*

Jason has been a medical doctor since 2018 and currently works as a pediatric resident n.i.t. in the OLVG hospital in Amsterdam. He is also a PhD candidate at the Emma Children's Hospital where he investigates the occurrence of complications of perinatal HIV infection in adolescents. While using effective therapy, these adolescents have a normal life expectancy. Therefore, it is important to understand how they grow up with this chronic illness. He is currently working on two topics within his PhD, namely lipidome and cardiovascular risk and neurological outcomes in adoption-status matched groups. He has written four articles, of which three have been published. His presentation at this year's NCHIV is on longitudinal assessment of cerebral blood flow in adolescent with a treated perinatal HIV infection. He expects to finish his PhD in the beginning of 2022.

S19



**Jeffrey Koole**  
*GGD Amsterdam*

Jeffrey Koole (1992) graduated as a medical doctor with honours in 2020. In 2021, he started as a PhD candidate at the Public Health Service (GGD) of Amsterdam, for the Department of Infectious Diseases, Research and Prevention. His PhD projects focuses on HIV, blood-borne infections (BBI), sexually transmitted infections (STI) and sexual behavior among men who have sex with men (MSM). Data is used from the Amsterdam Cohort Studies (ACS), an open, observational cohort study.

S22



**Jeffrey Umotoy**  
*Amsterdam UMC*

After completing his bachelor's degree in biochemistry and cell biology at the University of California in San Diego (2015), Jeffrey worked as a research associate at the International AIDS Vaccine Initiative under Dr. Landais working on the characterization of broadly neutralizing antibodies from a cohort of volunteers from Sub-Saharan Africa. He then proceeded to pursue a master's degree in immunobiology at the University of Bonn (2020) and performed his thesis under the mentorship of Dr. Überla at the University of Erlangen-Nürnberg. For his master's thesis, he designed an antibody-based therapeutic and serodiagnostic tool against SARS-CoV-2. Currently, he is a Ph.D. student in the group of Dr. van Gils at the University of Amsterdam where he is using novel antibody engineering approach to design HIV-1 cure therapeutics.

S6



## Jelle van Schooten

*Amsterdam UMC*

Jelle van Schooten studied Biomedical Sciences at the Utrecht University, including a six-month exchange program at the National University of Singapore. He then moved to Amsterdam to start his master's degree in Biomedical Sciences with a specialization in infection and immunity at the University of Amsterdam. As part of the program, he worked for nine months at the California Institute of Technology (California) to work on novel approaches of HIV-1 vaccine development. In 2017, he received his master's degree (cum laude) and started his PhD in the laboratory of Dr. Marit van Gils at the Academic Medical Center in Amsterdam. Jelle studies the development of antibody responses in HIV-1 vaccinated animals and HIV-1 infected humans to inform future HIV-1 vaccine design efforts. He recently performed part of his PhD research at the Scripps Research Institute (California) and will present data from his stay there at the NCHIV.

O1



## Jori Symons

*UMC Utrecht*

Dr. Jori Symons is a senior researcher at the Laboratory of Associate Professors Monique Nijhuis and Annemarie Wensing at the University Medical Centre Utrecht, The Netherlands. In 2021 Jori joined the Nijhuis/Wensing laboratory to investigate HIV pathogenesis in the CNS and to perform CRISPR/Cas9 related HIV cure studies. Furthermore, he researches SARS-CoV-2 tropism. Jori obtained his PhD from the same institute at the Nijhuis/Wensing laboratory in 2014 investigating HIV co-receptor usage in relation to HIV pathogenesis and cure studies. In 2015 Jori joined the laboratory of Professor Sharon Lewin at the Peter Doherty Institute in Melbourne Australia to investigate HIV pathogenesis through the site of HIV integration. Additionally, he led a small team in curative studies focused on nanoparticle mediated delivery of latency reversal agents. He obtained several national and international grants for his work.

Session 2: Chair



## Judith Branger

*NVHB kwaliteitscommissie*

Judith Branger was trained as an infectious diseases specialist at the AMC and OLVG hospitals in Amsterdam, the Netherlands (2001-2008). In 2004, she received her PhD for the thesis titled 'mechanisms of immune activation during infection' (promotor prof dr T. van der Poll). Since 2008, she works at the Flevohospital in Almere, the Netherlands, where she started an outpatient clinic for PLWH and viral hepatitis. She is an active member of the NVHB. Furthermore, she is involved in several research projects and she is trainer of residents and interns Internal Medicine at the Flevohospital, Almere.

Session 1: panel 2021 NL Monitoring Report



**Kennedy d'Abreu de Paulo**  
*Maastricht University*

Kennedy d'Abreu de Paulo (MSc.) is an interdisciplinary researcher in the fields of neuromodulation, biomedical sciences, clinical neurophysiology, and social psychology. He contributed to different clinical research programs. Currently, he is investigating the psychosocial aspects of blood donations by MSM and the potential of these new policy measures on stigma reduction for individuals living with HIV.

S23



**Kim Sigaloff**  
*Amsterdam UMC*

Dr. Kim Sigaloff is an infectious diseases specialist at the Amsterdam UMC. In 2009 she joined PharmAccess, now AIGHD, to study the long-term clinical outcomes of people receiving antiretroviral treatment in sub-Saharan Africa. Her research focused on the impact viral load monitoring, drug-resistance and HIV subtypes on the outcome of antiretroviral treatment, among adults and children. At the Amsterdam UMC her research interests include the prevention of antimicrobial resistance by promoting evidence-based antibiotic therapy.

Spotlight sessions A and B: moderator



**Lavina Gharu**  
*UMC Utrecht*

Lavina Gharu is a Post-Doctoral researcher at the Translational Virology group, department of Medical Microbiology, UMC Utrecht. She is a basic research scientist with >10 years of experience in the area of HIV research. She completed her PhD in HIV virology at NARI at Pune, India in 2012. From 2012-2015, she received the Arturo Falaschi fellowship by ICGEB in Italy to understand "Post transcriptional regulation of HIV-1 gene expression during replication and reactivation from latency by MATR3 protein". From 2018-2020, she was awarded the Intramural AIDS research fellowship by NIH to conduct research at the Vaccine Research Center at NIH in USA. Her project at NIH aimed at understanding "HIV viral genetic diversity in viral reservoirs in infected individuals on and off therapy". At UMC, her project aims at "understanding HIV CNS infection, developing different microglial model systems to test antiretroviral drugs and mechanisms involved in HIV latency establishment".


S8



**Leanne Helgers**  
*Amsterdam UMC*

Leanne Helgers completed her Bachelor and Master degree at the Vrije Universiteit Amsterdam in biomedical sciences. Over the course of her degree, she became interested in research after working in multiple labs, with a special interest in the interaction of the immune system with pathogens. This has led Leanne to her current position as PhD-candidate at the Amsterdam UMC, in the host defense group lead by Prof. Geijtenbeek. Here, she is researching the interaction of dendritic cells (subsets) with various viruses. However, her favorite project includes the interaction of dendritic cells subsets with vaginal microbiota and how this influences HIV-1 infection and transmission. Here, they try to translate basic science research into clinical relevant ex vivo experiments to improve our knowledge of HIV-1 susceptibility in woman.

S3



## Louise van Eekeren

*Radboudumc*

Louise van Eekeren is PhD-candidate at the department of Infectious Diseases at the Radboudumc in Nijmegen. Her PhD focuses on biomarkers and mechanisms of non-alcoholic fatty liver disease and liver fibrosis amongst the large and diverse population of well-treated PWH included in the 2000HIV-project. In addition, she has studied CCR5 expression and its determinants in PWH included in the 200HIV study (referred to as the “pilot study” for the 2000HIV-project). Today she will present results of a cross-sectional study that compared CCR5 expression on immune cells between people living with HIV and HIV-uninfected controls and assessed correlations between CCR5 expression markers and host factors, the inflammatory proteome, and the metabolome.

S7



## Maaike Noorman

*Utrecht University*

Maaike Noorman is a 2nd year PhD candidate at Utrecht University. Her research is concerned with social engagement in HIV cure research. More specifically, she assesses awareness, importance and meaning of an HIV cure amongst people with HIV and key populations. Before starting her PhD, Maaike conducted research on factors associated with loss to follow up in antiretroviral therapy in South Africa, and parents’ experiences in sexual education in the Netherlands. Her educational background is in social policy and public health.

S30



## Marc Blaauw

*Radboudumc*

Marc Blaauw is an internist-infectiologist and started in 2019 with his PhD at the Radboud Center of Infectious Diseases in Nijmegen. He focused the last 2 years on finding biomarkers that correlate with HIV reservoir size. He also contributed to the establishment of a large Dutch cohort of people living with HIV (2000HIV project). In this project he focuses on biomarkers and mechanisms of developing cardiovascular diseases and immune persistence in people living with HIV. Today he will present a GWAS study conducted in the 200HIV cohort (referred to as the “pilot study” for the 2000HIV project) that reveals new potential genetic factors affecting the size and transcriptional activity of HIV-1 reservoirs.

O8



## Marc van der Valk

*SHM, Amsterdam UMC*

Prof. Marc van der Valk MD, PhD works as an internist-infectiologist at the department of Infectious Diseases of the Amsterdam UMC where he is the head of the HIV outpatient clinic and medical director at the DC Klinieken Amsterdam. Since 2021 he is director of the board of the stichting hiv monitoring (SHM). He has extensive clinical and research experience in HIV-care and viral hepatitis. From 2014-2020 he was Chairman of the Dutch Association of HIV treating physicians. His research is focussed on improving the understanding and management of co-morbidity and co-infection in people living with HIV. He is senior investigator of the AGEHIV study ([www.agehiv.nl](http://www.agehiv.nl)) He is currently member of the Dutch HCV and HBV treatment guidelines and was a member of the national HIV treatment guideline from 2013-2020.

Session 1: moderator panel 2021 NL Monitoring Report



**Maria Prins**  
*GGD Amsterdam*

Maria Prins is Professor of Public Health and the Epidemiology of Infectious Diseases at the Amsterdam UMC, University of Amsterdam. She is the head of the Department of Infectious Diseases, Research and Prevention at Public Health Service of Amsterdam. She is internationally acknowledged as a leading researcher in the public health field of HIV, sexually transmitted and bloodborne viruses. She leads several cohort studies. HIV projects are components of the HIV Elimination Transmission Amsterdam initiative, the H-TEAM, a city focused approach joining forces for a future with no new HIV infection and the City's policy brief on zero new HIV infections by 2026.

Session 1: panel 2021 NL Monitoring Report



**Marieke Nühn**  
*UMC Utrecht*

Marieke Nühn obtained her Master's biomedical sciences at the Utrecht University in 2020, with a specific focus on infectious diseases and immunity. During her master's program she performed an internship in the lab of Sharon Lewin at the Peter Doherty Institute in Melbourne, studying HIV integration sites and its effect on clonal proliferation of latently infected cells. In October 2020, she started as a PhD student in the group of Monique Nijhuis and Annemarie Wensing in the UMC Utrecht, the Netherlands. During this PhD project, she studies the HIV persistence in peripheral blood and the central nervous system, focusing on the quantification and characterisation of its reservoir.

07



**Marit van Gils**  
*Amsterdam UMC*

Marit van Gils (1982) studied medical pharmaceutical sciences at the University of Groningen, the Netherlands. She has performed her Ph.D. research (2007-2011) at the University of Amsterdam in the lab of Dr. Schuitemaker on the humoral immune response after HIV-1 infection. She continued her career as a postdoctoral fellow in the lab of Dr. Sanders working on the development of an HIV protein vaccine at the Academic Medical Center in Amsterdam, the Netherlands. Marit has also performed part of her postdoctoral research at the Scripps Research Institute in the lab of Dr. Burton (2013-2016) and in 2017 started her own research group at the Amsterdam UMC, the Netherlands, studying the antibody and B cell responses after infection and vaccination, including HIV-1, Influenza and SARS-CoV-2.

Spotlight sessions A and B: moderator





## Mark Vermeulen

*Executive Director Aidsfonds*

Mark Vermeulen is Executive Director of Aidsfonds – Soa Aids Nederland. Mark started his career at the Dutch NGO Evert Vermeer Foundation and worked as part of the United Nations Development Program (UNDP). Mark has over 10 years of experience in the (international) fight against AIDS and STDs.

Having lived with HIV since 2007, Mark has a strong personal commitment to the movement that aims to put an end to AIDS. Mark: “Whether you have access to life-saving medication all depends on where you are born. In the Netherlands I can live a normal life with HIV, but that is not the case for everyone. Especially in other places in the world, this is not always the case. My aim is to end this inequality.”

In the Netherlands, he is responsible for the Netherlands to Zero, a movement to bring the number of new HIV infections to zero as quickly as possible. As director of Aidsfonds – Soa Aids Nederland, Mark chooses an ambitious course, in which cooperation with communities is key.

Mark has held several positions at Aidsfonds – Soa Aids Nederland. Starting as a lobbyist, he played a key role in keeping HIV and AIDS on the Dutch development agenda. Later on, he contributed to the rollout of Aidsfonds’ international sex work program. As Program Manager, he had a leading role in the international human rights program Bridging the Gaps. As from 2015, this is the largest program worldwide committed to improving the health and rights of key populations in the fight against AIDS.

Mark has an MBA from the Rotterdam School of Management Erasmus University). In addition, he holds a Master in Political Science and American Studies at the University of Amsterdam.

Session 4: 40 Years of AIDS



## Mouraya Hussein

*Amsterdam UMC*

Mouraya Hussein is a third year PhD student at the Amsterdam UMC. She is part of the Medical Microbiology department at the Amsterdam UMC and her PhD track is supervised by Prof. Berkhout and Dr. Herrera-Carrillo. Their group focuses on the development of a cure for HIV infection based on novel CRISPR-Cas methods. Specifically, her work focuses on the design of CRISPR-Cas13 therapeutics targeting HIV and SARS-CoV-2 RNA in order to inhibit viral replication. Moreover, she is testing a novel HIV-inactivation strategy that induces a state of superinfection resistance, while clearing the infection using the DNA targeting CRISPR-Cas9 system.

S5



## Myrthe Verburgh

*Amsterdam UMC*

After studying medicine at the University of Amsterdam, Myrthe Verburgh worked for one year as a resident at the department of Internal Medicine at Tergooi Hospital in Hilversum. Since February 2020, she is working as a PhD candidate at the AGEHIV Cohort Study (AIGHD, Amsterdam UMC-location AMC, GGD Amsterdam). Together with the AGEHIV study team, she helped design and coordinate the AGEHIV COVID-19 substudy. Main part of her research focuses on incidence of SARS-CoV-2 infection and SARS-CoV-2 immune responses after infection and COVID-19 vaccination in people living with HIV.

O2



## Natasja van Holten

**LUMC**

Natasja van Holten has been working as a HIV nurse consultant at Leiden University Medical Center (LUMC) in Leiden since 2015. From 2017 to 2021 she was treasurer on the board of the Dutch Society of HIV nurses (V&VN VCH) and she has been chair of this department since January 2021. The VCH has distinguished itself for 33 years as one of the first professional and organized departments for specialized nurses. In '40 years of HIV', fewer and fewer nurses and nurse practitioners specialized in HIV-care have experienced all decades from AIDS to now HIV care in the Netherlands. Including herself. Even today, that knowledge, expertise, and activism remain very valuable for our current and new generation of nurse professionals in Dutch HIV care. As chairman, she considers it is an honor to represent the VCH with all cooperation partners.

Session 3: panel Long-acting ART: a paradigm shift



## Neeltje Kootstra

**Amsterdam UMC**

Neeltje Kootstra performed her Ph.D. research at the University of Amsterdam in the lab of Prof. Schuitemaker on HIV-1 infection in macrophages. She continued her work on HIV-1 and lentiviral vectors as a postdoctoral researcher at the Lab of Genetics at Salk Institute, La Jolla, USA. In 2003 she returned to the Netherlands and set up her own research group to study host-virus interactions. Currently, she is an associate professor at the Department of Experimental Immunology and head of the Laboratory for Viral Immune Pathogenesis at the Amsterdam UMC.

Spotlight session C: moderator



## Nicolas Chomont

**University of Montreal**

Dr. Nicolas Chomont is an Associate research professor in the Department of Microbiology, Infectiology and Immunology at the Université de Montréal. His laboratory is located at the Research Center of the CHUM (CRCHUM). Dr. Chomont received his doctorate in medical virology at the Pierre and Marie Curie University (Paris VI) under the direction of Prof. Laurent Bélec in the laboratory of Prof. Michel Kazatchkine. He studied the interactions between HIV and genital mucosa and their implications for the sexual transmission of the virus. Between 2004 and 2009, he completed a postdoctoral internship in Dr. Rafick Sékaly's laboratory at the Université de Montréal and the CRCHUM. His work has led to the identification of the cellular reservoirs of HIV that are responsible for the persistence of the virus during antiretroviral therapies. Dr. Chomont then moved to VGTI-Florida where he was named "Associate Member". As an independent researcher, he has continued to characterize viral reservoirs as the major obstacle to the eradication of HIV. Since January 2015, Dr. Chomont has joined the Université de Montréal and the CRCHUM where he leads a research program aimed at dissecting the molecular and immunological mechanisms involved in viral latency and developing new therapeutic strategies aimed at Elimination of HIV reservoirs.

IP-02



## Ninée Buchholtz

*UMC Utrecht*

Ninée Buchholtz obtained her Master's biomedical sciences at the University of Amsterdam in 2019. During her master's program she performed a research internship at Mount Sinai School of medicine in New York city and performed a literature internship at the AIDS fund. This literature study was focused on new cure interventions for HIV-1 eradication. She started in 2019 as a PhD student in the group of Monique Nijhuis and Annemarie Wensing in the UMC Utrecht, the Netherlands. During this PhD project, she studies the HIV-1 subtype C reservoir and also focuses on cure interventions based on latency reversal agents.

S28



## Patrick Oomen

*UMC Utrecht*

Patrick Oomen (1993) obtained his degree in Medicine from Utrecht University/UMC Utrecht in 2019 after which he worked as a physician not in training to be a specialist (ANIOS) in internal medicine. He currently works as a PhD candidate at the UMC Utrecht, researching various antiretroviral therapy- and disease-related outcomes such as neurocognition, pulmonary function, immune activation and residual viremia in HIV. Patrick has also conducted research on prognostic markers in sepsis and the adequacy of antibiotic prescribing in the emergency department. To further enhance his research skills, he currently follows the MSc Epidemiology at Utrecht University.

S31



## Peter Reiss

*Amsterdam UMC, University of Amsterdam & Amsterdam Institute for Global Health and Development*

Peter Reiss is Emeritus Professor of Medicine at the Amsterdam UMC, University of Amsterdam, the Netherlands. He maintains a guest appointment in the Department of Global Health and continues his research through the Amsterdam Institute for Global Health and Development.

Professor Reiss served as the Director of the Netherlands HIV Monitoring Foundation until April 2021. He is a member of the Scientific Advisory Board of the Pierre Louis Institute of Epidemiology and Public Health in Paris, France, the US NIH/NIAID HIV Vaccine Data and Safety Monitoring Board, and programme committee member of CROI, the EACS Conference and HIV Glasgow.

He served as EACS President (2008-2012), on the Governing Council of IAS (2006 – 2014), and as co-chair of the 22nd International AIDS Conference (AIDS 2018).

Professor Reiss is clinical HIV section editor for Antiviral Therapy. His research largely focuses on the long-term complications of HIV and HIV treatment, and more particularly in relation to ageing.

Session 4: 40 Years of AIDS



**Philippe Adam**  
*IPSR Utrecht, UNSW Sydney*

Dr Philippe CG Adam is Senior Research Fellow at UNSW Sydney and Director of the Institute for Prevention and Social Research located in Utrecht and Bangkok. Philippe has a background in social sciences and an interest in social and behavioural change. In the past three decades, he has been leading research on the sexuality and health of men who have sex with men (MSM) and young people in Europe, Australia and Asia. Philippe is currently studying how MSM in the Netherlands and Thailand navigate the COVID-19 pandemic.

S27



**Piter Oosterhof**  
*OLVG*

Piter Oosterhof graduated in 2012 from the University of Groningen. Since 2013 he has been working in the hospital pharmacy of OLVG in Amsterdam, where he completed his training as an outpatient pharmacist. He has a special interest in oncology, palliative care and HIV. Since 2018 he has started his PhD research at the Radboudumc in Nijmegen on the subject 'the effective use of antiretroviral therapy'. He is also a member of various committees within the professional associations NVZA and KNMP.

Session 3: panel 'Long-acting ART: a paradigm shift?' | S21



**Renée Schreurs**  
*Amsterdam UMC*

Renée Schreurs is a postdoctoral fellow in the Autophagy-directed Immunity lab headed by dr. Carla Ribeiro at the Department of Experimental Immunology, Amsterdam UMC (location AMC). She holds a MSc in Neuroscience and completed a PhD on the development of mucosal T cell immunity in the early-life intestine. Within dr. Ribeiro's lab, Renee's current research focuses on investigating the impact of genetic variation in autophagy pathways on T cell functionality in the context of viral infections such as HIV-1. Ultimately, the Autophagy-directed Immunity lab aims to harness the therapeutic potential of targeting autophagy mechanisms to intervene with HIV-1, Dengue virus, and SARS-CoV-2 infections.

O9



**Reon van Dyk**  
*ViiV Healthcare*

Reon van Dyk, qualified as Internist in 2003 in Cape Town, South Africa. He spent most of his career to date as Physician in HIV clinical practice and was passionate about preventive HIV medicine, including Prevention of Mother-To-Child Transmission and Pre-exposure Prophylaxis. Reon participated in the consensus committee of the first South African PrEP guidelines and he was a co-founder of a successful PositiveHeroes Anti-stigma campaign, a multimedia initiative focussing on the normalisation of living meaningful with HIV. Reon joined ViiV Healthcare Netherlands in 2019 as Medical Lead for the long-acting regimen and has become appreciative of the tailor-made treatment options currently available to address the specific needs of each person living with HIV.

S33



## Rogier Sanders

*Amsterdam UMC*

Rogier Sanders (1975) studied Medical Biology at the University of Amsterdam and the Rockefeller University in New York. In 2004 he obtained his Ph.D. (cum laude) from the University of Amsterdam. Rogier currently is a Professor of Virology in Amsterdam and holds an affiliate faculty position at Weill Medical College of Cornell University in New York City. His research focuses on the design of viral vaccine candidates based on stabilized surface proteins. For example, he invented stabilized native-like HIV-1 envelope trimers (SOSIP trimers), several of which are currently in phase I clinical studies. He also works on vaccine candidates against SARS-CoV-2, Lassa virus and hepatitis C virus. In 2011, he received the Dutch Prize for Biochemistry and Molecular Biology. Rogier has (co-)authored over 200 articles, including in journals such as Nature, Science, Lancet and Cell.

Session 1: Chair



## Sarah Stutterheim

*Maastricht University*

Dr. Sarah Stutterheim is an interdisciplinary mixed methods researcher with expertise in the related fields of health and social psychology, health promotion, and public health. Her research focuses on psychosocial aspects of living with a given condition or identity. As such, Dr. Stutterheim's research often focuses on social stigma and its effects, particularly among vulnerable populations, across a broad range of conditions and identities. A core area of her research is HIV, where she investigates psychosocial aspects of HIV across the continuum from primary prevention to testing, linkage to care, initiation, and adherence. She also conducts research on systematic behaviour change more broadly, on sexual and reproductive health, and on LGBTQI+ issues. Dr. Stutterheim's research is strongly informed by principles of community engagement, the use of participatory research methods, and explicit attention to inclusivity.

O10



## Shirley Man

*Amsterdam UMC*

Shirley completed her Master's in Biomedical Sciences (Research Specialization) at Leiden University and graduated by the end of 2018. Afterwards, she worked as a technician at the RIVM before starting her PhD at the department of Experimental Immunology at the Amsterdam UMC, location AMC in the beginning of 2020. She is currently working on HIV-1 cure research and specifically focuses on the detection of the viral reservoir. Her project is led by dr. Neeltje Kootstra, prof. dr. Theo Geijtenbeek, and dr. Carla Ribeiro and is part of the Target2Cure consortium, a joint research program comprised of several research groups and partners from industry.

S4



**Silke David**  
*RIVM*

Silke David works as a senior policy advisor at the Centre for Infectious Diseases Control (CIb) at the National Institute of Health and the Environment (RIVM), Bilthoven, the Netherlands. Currently she also works as a program manager of STI, HIV and sexual health. As part of this job she strengthens relations and cooperation between the various stakeholders receiving subsidies from the RIVM-CIb. Among the recipients are national expert centers like Rutgers and STI-Aids-Netherlands as well as Centers for Sexual Health at Municipal Public Healthcare services. Also, she advises both the director of the RIVM-CIb and the Ministry of Health about issues relating to STI, HIV and sexual health. She has facilitated the National Action Plan STI, HIV and sexual health 2017-2022 as well as the development of the National Hepatitis Plan, commissioned by the Ministry of Health.

Spotlight sessions A and B: moderator



**Soerajja Bhoelan**  
*UMC Groningen*

Soerajja Bhoelan (1994) works as a PhD candidate at the department of Haematology – section Haemostasis and Thrombosis of the University Medical Center Groningen (UMCG) under the supervision of prof dr. Karina Meijer and dr. Vladimir Tichelaar. Before starting her PhD, Soerajja obtained her medical degree at Utrecht University in 2018. Her research focuses on the different aspects of infection and inflammation, in venous thromboembolism, including HIV infection in collaboration with Dr. Wouter Bierman. Next to her research, she also works as a coagulation doctor at the outpatient clinics for Haemostasis and Thrombosis.

S20



**Stephanie Gumbs**  
*UMC Utrecht*

Stephanie Gumbs is a PhD student in Infection and Immunity at UMC Utrecht and is currently finalizing her doctoral work. Her dissertation explores the central nervous system as a viral reservoir for HIV during combination antiretroviral therapy. In particular, she characterized cerebral organoids as a novel CNS culture model for HIV research and is currently studying DNA isolated from HIV-infected microglia obtained from the Manhattan HIV Brain Bank. Her research is supported by the Aidsfonds and Health Holland. She can be contacted at [s.b.h.gumbs@umcutrecht.nl](mailto:s.b.h.gumbs@umcutrecht.nl).

S16



**Steven de Taeye**  
*Amsterdam UMC*

Steven de Taeye (1988) studied biomedical sciences at the University of Amsterdam. He performed his Ph.D. research (2012-2017) at the University of Amsterdam in the group of Dr. Sanders, where he worked on the development of an envelope glycoprotein based HIV-1 vaccine by stabilizing the envelope glycoprotein in a native-like conformation. After his PhD, he continued his career as a postdoctoral fellow at Sanquin in the group of Dr. Vidarsson and Dr. Rispen, studying the influence of IgG polymorphisms on the Fc-mediated effector functions of antibodies. Last year he received a young investigator grant from the AIDS fonds and returned to the Amsterdam UMC to work on various antibody engineering strategies to improve broadly neutralizing antibodies for HIV-1 cure research.

S9



**Sven Danner**  
*Amsterdam UMC*

Professor Sven Danner, born in 1946, studied medicine and was registered as internist in 1977. He became head of the outpatient department of internal medicine in the Academic Medical Center in Amsterdam. It was there that the first Dutch patients were admitted with the completely new and fatal disease, soon thereafter known as Aids. He founded the first clinical ward especially for Aids patients. Together with professor Joep Lange and professor Peter Reiss he has been involved in numerous clinical trials, mainly in the field of antiretroviral therapy. In 1997 he was one of the co-founders of the Dutch Society of Aids Treating Physicians, later converted into the Dutch Society of HIV Treating Physicians.


Session 3: Intro



**Tamika Marcos**  
*Maastricht University*

Tamika Marcos is a 2nd year PhD-student at Maastricht University. Her research focuses on the social scientific side of HIV Cure. She conducts research on three major topics within the HIV Cure field: the meaningful involvement of people with HIV in HIV Cure research, the impact of a possible cure on HIV-related stigma and the importance of language. As such, community engagement is an important factor in her research. Tamika has an educational background in European Public Health and Health Education and Promotion.

S18



**Tania Mudrikova**  
*UMC Utrecht*

Tania Mudrikova, MD, PhD, is specialist in internal medicine and infectious diseases at the University Medical Center in Utrecht where she also completed her residency. She works with people with HIV since 2001. Her special interests are women with HIV and complex patients like those with longstanding HIV, resistance issues or organ transplants. She is a member of the treatment guideline committee of the Dutch Association of HIV-treating Physicians (NVHB) and the SHM Advisory Board. Next to her activities regarding infectious diseases, she also is a member of the medical ethics committee and leads a hospitalist residency programme, both at the UMC Utrecht.

Session 1: Chair



**Thomas Nieuwenstein**  
*Radboudumc*

Thomas Nieuwenstein is 21 years old, and he is currently in his final year of the master's programme Biomedical Sciences at the Radboud University Medical Center, Nijmegen, The Netherlands. In his studies, he is focusing on the various aspects of the drug development pipeline through different courses in the Drug Safety & Toxicology and the Immunology & Host Defense specialisations.

The abstract is the result of his first master's internship, in which he learned a lot about HIV, in silico modelling, and science in general. This is the first time he will be presenting the findings outside of the departmental or educational setting. He is excited to meet you and answer your questions at NCHIV!

S24



**Tom Jacobs**  
*Radboudumc*

Tom Jacobs is a pharmacist and a 3rd year PhD student at the Radboud University Medical Center Pharmacy department. The focus of his research is on clinical pharmacology of anti-infectives in children living with HIV and access to medicines. Tom is the project coordinator for pharmacokinetic sub-studies within large international multicenter clinical trials in various sub-Saharan African countries; the EMPIRICAL trial (investigating empirical CMV and TB treatment for ints with HIV and severe pneumonia) and the D3 trial (a registrational study for a new paediatric fixed-dose combination tablet of dolutegravir/lamivudine).

S12



**Vita Jongen**  
*GGD Amsterdam*

Vita Jongen has a bachelor in psychobiology from the University of Amsterdam and a master in epidemiology from the University of Utrecht. During her master she specialized in epidemiology of infectious diseases. During her PhD she primarily focusses on sexually transmitted infections, especially human papillomavirus and pre-exposure prophylaxis. Currently she is a post-doc researcher at the Department of Infectious Diseases at the Public Health Service Amsterdam.

S14



**Wilma Brokking**  
*DC Klinieken Amsterdam*

Wilma Brokking, advanced nurse practitioner, has been working in the HIV care since 2008. In the early days of her career she was active in primary health care, running a 'home-based' practice in Amsterdam in cooperation with a general practitioner. Furthermore she has experience in the psychiatry, hospitals and in terminal and sepulture care. Besides her daily activities, she is involed in the LHBTQ community by giving workhops and presentations and take part in the debate. Consistently she advocates the importance of personal and holistic care with attention for sexuality and stigma. Every day she strives for expertness, involvement and reliability. Her medical specialties include HIV, hepatitis, STD's en PreEP.

Session 1: panel 2021 NL Monitoring Report



**Wouter Bierman**  
*UMC Groningen*

Wouter Bierman (1974) has worked as infectious diseases specialist at the department of internal medicine of the University Medical Center Groningen (UMCG) since 2010. At the UMCG he is head of the infectious diseases section, director of the infectious diseases fellowship program and head of the outpatient clinic for infectious diseases. His main scientific interests are prevention of comorbidities in HIV and the impact of COVID on people living with HIV. He is currently chair of the national HIV treatment guideline committee.

Spotlight session C: moderator



